These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 12149456)

  • 1. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
    Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
    Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
    Nardi V; Azam M; Daley GQ
    Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
    Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
    Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Manley PW; Cowan-Jacob SW; Mestan J
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
    Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
    Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.